Novo Integrated Sciences, Inc.
NVOS · OTC
8/31/2024 | 5/31/2024 | 2/29/2024 | 11/30/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -2.3% | -0.6% | -18.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 51.2% | 28.5% | 41.8% | 50% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 235.3% | -320.3% | -29.1% | -73.7% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 162.4% | -436% | -86.6% | -120.3% |
| EPS Diluted | 0.26 | -0.74 | -0.16 | -0.28 |
| % Growth | 135.1% | -362.5% | 42.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |